Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.

Literature DB >> 27668052

Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.

Lisa A Raedler.

Abstract

Entities: Chemical Disease Species

Year: 2016 PMID： 27668052 PMCID： PMC5013861

Source DB: PubMed Journal: Am Health Drug Benefits ISSN： 1942-2962

× No keyword cloud information.

7 in total

1. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

Authors: Zachary R Hunter; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Robert J Manning; Christina Tripsas; Christopher J Patterson; Patricia Sheehy; Steven P Treon
Journal: Blood Date: 2013-12-23 Impact factor: 22.113

2. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors: Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal: N Engl J Med Date: 2012-08-30 Impact factor: 91.245

3. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Authors: Kenneth C Anderson; Melissa Alsina; William Bensinger; J Sybil Biermann; Adam D Cohen; Steven Devine; Benjamin Djulbegovic; Edward A Faber; Christine Gasparetto; Francisco Hernandez-Ilizaliturri; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Bruno C Medeiros; Ruby Meredith; Noopur Raje; Jeffrey Schriber; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Guido Tricot; Donna M Weber; Joachim Yahalom; Furhan Yunus; Rashmi Kumar; Dorothy A Shead
Journal: J Natl Compr Canc Netw Date: 2012-10-01 Impact factor: 11.908

4. Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors: Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal: N Engl J Med Date: 2015-04-09 Impact factor: 91.245

5. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors: Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal: Blood Date: 2013-07-08 Impact factor: 22.113

Review 6. Ibrutinib and novel BTK inhibitors in clinical development.

Authors: Akintunde Akinleye; Yamei Chen; Nikhil Mukhi; Yongping Song; Delong Liu
Journal: J Hematol Oncol Date: 2013-08-19 Impact factor: 17.388

Review 7. Waldenstrom macroglobulinemia: prognosis and management.

Authors: A Oza; S V Rajkumar
Journal: Blood Cancer J Date: 2015-03-27 Impact factor: 11.037

7 in total

4 in total

1. In silico immune infiltration profiling combined with functional enrichment analysis reveals a potential role for naïve B cells as a trigger for severe immune responses in the lungs of COVID-19 patients.

Authors: Yi-Ying Wu; Sheng-Huei Wang; Chih-Hsien Wu; Li-Chen Yen; Hsing-Fan Lai; Ching-Liang Ho; Yi-Lin Chiu
Journal: PLoS One Date: 2020-12-02 Impact factor: 3.240